Abnormal liver chemistry tests indicating hepatic dysfunction are a common finding in critically ill patients [1]. Hepatobiliary enzyme levels interpreted in isolation convey information on the level of ongoing injury; bilirubin, albumin, and international normalized ratio convey information on liver function; and platelets convey information on severity of fibrosis [2]. Hepatic dysfunction must be interpreted in the clinical context of a given patient because the numerous liver biomarkers indicate different pathways of hepatic dysfunction and can be influenced by extrahepatic factors such as age, diet, or pregnancy [3]. Particularly, hepatic dysfunction is closely related to clinical outcome in the critically ill and is included in most of the widely used clinical risk scoring systems in the setting of intensive care unit such as Acute Physiology and Chronic Health Evaluation II (APACHE II; cirrhosis as a factor), Sequential Organ Failure Assessment (SOFA; bilirubin as components), or Simplified Acute Physiology Score (SAPS; bilirubin as components) [4]. Hypoalbuminemia, which is a component variable in APACHE III, was also related to clinical outcome in acute ill patients and its association may reflect nutritional status and inflammation [5]. Accordingly, we suspect that the prognostic power of bilirubin/albumin ratio would be better than that of bilirubin or albumin alone.